TCR2 Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 58

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $165M

  • Investors
  • 3

TCR2 Therapeutics General Information

Description

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Contact Information

Website
www.tcr2.com
Formerly Known As
TCR2, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Binney Street
  • Suite 710
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 100 Binney Street
  • Suite 710
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TCR2 Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 06-Mar-2023 $165M Completed Generating Revenue
6. 2PO 21-Jan-2021 Completed Generating Revenue
5. 2PO 29-Jul-2020 Completed Generating Revenue
4. IPO 14-Feb-2019 Completed Clinical Trials - General
3. Early Stage VC (Series B) 21-Mar-2018 Completed Startup
2. Early Stage VC (Series A) 07-Dec-2016 $44.5M $44.5M Completed Startup
1. Early Stage VC 01-Jan-2015 Completed Startup
To view TCR2 Therapeutics’s complete valuation and funding history, request access »

TCR2 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view TCR2 Therapeutics’s complete cap table history, request access »

TCR2 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell t
Drug Discovery
Cambridge, MA
58 As of 2023

Bethesda, MD
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TCR2 Therapeutics Competitors (64)

One of TCR2 Therapeutics’s 64 competitors is Northwest Biotherapeutics, a Corporation company based in Bethesda, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Northwest Biotherapeutics Corporation Bethesda, MD
Kite Pharma Formerly VC-backed Santa Monica, CA
Monte Rosa Therapeutics Formerly VC-backed Boston, MA
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 64 competitors. Get the full list »

TCR2 Therapeutics Patents

TCR2 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023235479-A1 Compositions and methods for treating cancer Inactive 02-Jun-2022
WO-2023172967-A2 Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins Inactive 09-Mar-2022
WO-2023172967-A3 Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins Inactive 09-Mar-2022
WO-2023133424-A2 Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides Inactive 05-Jan-2022
WO-2023133424-A3 Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides Inactive 05-Jan-2022 A61K40/11
To view TCR2 Therapeutics’s complete patent history, request access »

TCR2 Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TCR2 Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
6 Dimensions Capital Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
ArrowMark Partners Asset Manager Minority
Cathay Capital PE/Buyout Minority
Curative Ventures Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

TCR2 Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view TCR2 Therapeutics’s complete esg history, request access »

TCR2 Therapeutics FAQs

  • When was TCR2 Therapeutics founded?

    TCR2 Therapeutics was founded in 2015.

  • Where is TCR2 Therapeutics headquartered?

    TCR2 Therapeutics is headquartered in Cambridge, MA.

  • What is the size of TCR2 Therapeutics?

    TCR2 Therapeutics has 58 total employees.

  • What industry is TCR2 Therapeutics in?

    TCR2 Therapeutics’s primary industry is Drug Discovery.

  • Is TCR2 Therapeutics a private or public company?

    TCR2 Therapeutics is a Private company.

  • What is the current valuation of TCR2 Therapeutics?

    The current valuation of TCR2 Therapeutics is .

  • What is TCR2 Therapeutics’s current revenue?

    The current revenue for TCR2 Therapeutics is .

  • How much funding has TCR2 Therapeutics raised over time?

    TCR2 Therapeutics has raised $509M.

  • Who are TCR2 Therapeutics’s investors?

    6 Dimensions Capital, Alexandria Venture Investments, ArrowMark Partners, Cathay Capital, and Curative Ventures are 5 of 13 investors who have invested in TCR2 Therapeutics.

  • Who are TCR2 Therapeutics’s competitors?

    Northwest Biotherapeutics, Kite Pharma, Monte Rosa Therapeutics, Carisma Therapeutics, and Allogene Therapeutics are some of the 64 competitors of TCR2 Therapeutics.

  • When was TCR2 Therapeutics acquired?

    TCR2 Therapeutics was acquired on 06-Mar-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process